These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38354828)

  • 1. Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions.
    Li X; Wu M; Lu J; Yu J; Chen D
    Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189084. PubMed ID: 38354828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological effects of IL-21 on immune cells and its potential for cancer treatment.
    Ma M; Xie Y; Liu J; Wu L; Liu Y; Qin X
    Int Immunopharmacol; 2024 Jan; 126():111154. PubMed ID: 37977064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.
    Liu K; Huang A; Nie J; Tan J; Xing S; Qu Y; Jiang K
    Front Immunol; 2021; 12():683332. PubMed ID: 34093586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment.
    Yi P; Yu W; Xiong Y; Dong Y; Huang Q; Lin Y; Du Y; Hua F
    Mol Cancer Ther; 2024 Feb; 23(2):148-158. PubMed ID: 37988561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
    Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
    Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members.
    Nagai H; Oniki S; Fujiwara S; Yoshimoto T; Nishigori C
    Immunotherapy; 2010 Sep; 2(5):697-709. PubMed ID: 20874653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antitumor immunotherapy].
    Błoński JZ; Warzocha K
    Postepy Hig Med Dosw; 1994; 48(6):701-28. PubMed ID: 7675731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment.
    Kuo CL; Chou HY; Lien HW; Yeh CA; Wang JR; Chen CH; Fan CC; Hsu CP; Kao TY; Ko TM; Lee AY
    Cancer Immunol Immunother; 2023 Feb; 72(2):351-369. PubMed ID: 35895109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukins and cancer immunotherapy.
    Yoshimoto T; Morishima N; Okumura M; Chiba Y; Xu M; Mizuguchi J
    Immunotherapy; 2009 Sep; 1(5):825-44. PubMed ID: 20636026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and applications of interleukins in cancer immunotherapy.
    Anestakis D; Petanidis S; Kalyvas S; Nday CM; Tsave O; Kioseoglou E; Salifoglou A
    Int J Mol Sci; 2015 Jan; 16(1):1691-710. PubMed ID: 25590298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family.
    Soler MF; Abaurrea A; Azcoaga P; Araujo AM; Caffarel MM
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37945321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy.
    Han ZJ; Li YB; Yang LX; Cheng HJ; Liu X; Chen H
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Development Status of Cytokines for Cancer Immunotherapy.
    Song K
    Biomol Ther (Seoul); 2024 Jan; 32(1):13-24. PubMed ID: 38148550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy.
    Mortezaee K; Majidpoor J
    Cell Oncol (Dordr); 2022 Jun; 45(3):333-353. PubMed ID: 35587857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioengineering strategies to enhance the interleukin-18 bioactivity in the modern toolbox of cancer immunotherapy.
    Taheri M; Tehrani HA; Daliri F; Alibolandi M; Soleimani M; Shoari A; Arefian E; Ramezani M
    Cytokine Growth Factor Rev; 2024 Feb; 75():65-80. PubMed ID: 37813764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IL-2 cytokine family in cancer immunotherapy.
    Sim GC; Radvanyi L
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):377-90. PubMed ID: 25200249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.
    Shafqat A; Omer MH; Ahmed EN; Mushtaq A; Ijaz E; Ahmed Z; Alkattan K; Yaqinuddin A
    Front Immunol; 2023; 14():1200941. PubMed ID: 37520562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.